GlobalData on MSN1d
Autolus secures FDA approval for CAR-T cell therapy use in ALLAutolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...
Producing herbal medicines on an industrial scale is challenging. However, a team of bioengineers from Kobe University has ...
Researchers found that neural crest stem cells are uniquely capable of reprogramming, challenging current reprogramming ...
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...
Hosted on MSN4d
New CAR T-Cell Therapy Approved for LeukemiaThe FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...
Neural crest stem cells, a rare type found in skin and other tissues, are uniquely capable of reprogramming into different ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...
The therapy was cleared to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL) after showing complete remission in 63% of efficacy evaluable patients during Autolus’ ...
The FDA has approved obecabtagene autoleucel (Aucatzyl) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Aucatzyl is a CAR T-cell therapy that targets CD19 and has been designed to minimize excessive activation of the programmed T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback